The Company received clearance for the NanoKnife System for prostate tissue ... prostate tissue in patients with intermediate-risk prostate cancer (PCa). Conducted in collaboration with the ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ...

1 The study’s results validated the robust safety and clinical efficacy profile of the NanoKnife System, reinforcing findings from more than 32 clinical studies performed around the ...

European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. About AngioDynamics, Inc. AngioDynamics is a leading and ...

expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate ...

The clearance for the NanoKnife System for prostate tissue ... ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). The latest regulatory clearance is a significant ...

It is worthwhile to note that the PRESERVE clinical study assessed the safety and effectiveness of the NanoKnife System for ablating prostate tissue in patients with intermediate-risk prostate cancer ...

"The NanoKnife System minimizes the life-altering ... of the NanoKnife System in patients with immediate-risk prostate cancer. The results reinforced findings from more than 32 other studies ...